Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Staphylococcus aureus | Peptide deformylase | Starlite/ChEMBL | References |
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | Peptide deformylase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trichomonas vaginalis | abca6, putative | Peptide deformylase | 183 aa | 162 aa | 25.3 % |
Loa Loa (eye worm) | adipor-like receptor | Peptide deformylase | 203 aa | 163 aa | 23.9 % |
Trypanosoma cruzi | hypothetical protein | Peptide deformylase | 183 aa | 155 aa | 22.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | DNA gyrase subunit B | 0.0782 | 0.5891 | 0.3533 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.0194 | 0.0391 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0558 | 0.3646 | 1 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.0194 | 0.0391 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0279 | 0.0853 | 1 |
Plasmodium falciparum | DNA gyrase subunit B | 0.1192 | 1 | 1 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0213 | 0.0194 | 0.0391 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0279 | 0.0853 | 0.5 |
Giardia lamblia | DNA topoisomerase II | 0.0241 | 0.0479 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0689 | 0.4963 | 1 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0279 | 0.0853 | 0.5 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0279 | 0.0853 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0558 | 0.3646 | 0.3053 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0279 | 0.0853 | 0.5 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0213 | 0.0194 | 0.0391 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.0194 | 0.0391 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.1192 | 1 | 1 |
Plasmodium vivax | peptide deformylase, putative | 0.0558 | 0.3646 | 0.3053 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.1192 | 1 | 1 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0213 | 0.0194 | 0.0391 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0279 | 0.0853 | 0.5 |
Brugia malayi | Probable DNA topoisomerase II | 0.0279 | 0.0853 | 0.5 |
Schistosoma mansoni | DNA topoisomerase II | 0.0279 | 0.0853 | 0.5 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0279 | 0.0853 | 0.5 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.1192 | 1 | 1 |
Trypanosoma brucei | DNA topoisomerase ii | 0.0689 | 0.4963 | 1 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.0689 | 0.4963 | 1 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.0194 | 0.0391 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0689 | 0.4963 | 1 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0279 | 0.0853 | 0.5 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.1192 | 1 | 1 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.1192 | 1 | 1 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0279 | 0.0853 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0558 | 0.3646 | 0.6796 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0279 | 0.0853 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0689 | 0.4963 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.9 nM | Inhibition of Streptococcus pneumoniae PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
IC50 (binding) | = 4.5 nM | Inhibition of Staphylococcus aureus PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.